面肩肱型肌营养不良症的管理策略
Management strategies in facioscapulohumeral muscular dystrophy.
作者信息
Lu Junren, Yao Zhenjun, Yang Yi, Zhang Chi, Zhang Jian, Zhang Ying
机构信息
Department of Orthopedic Surgery, Zhongshan Hospital affiliated with Fudan University, Shanghai, China.
Department of Nursing, Zhongshan Hospital affiliated with Fudan University, Shanghai, China.
出版信息
Intractable Rare Dis Res. 2019 Feb;8(1):9-13. doi: 10.5582/irdr.2019.01016.
Abstract
Facioscapulohumeral muscular dystrophy (FSHD) also known as Landouzy-Dejerine disease, is an autosomal-dominant disorder of the skeletal muscles with the name according to the various muscle groups it affects: the face, shoulders and upper arms. It is the third most common genetic degenerative disorder of the skeletal muscles without specific patterns in all the affected individuals. At present there is no cure for the disease but numerous management strategies are available to improve the quality of life and prevent further degeneration of various muscle groups. This review aims to provide an insight on the management strategies for FSHD patients including both lifestyle and medical intervention.
摘要
面肩肱型肌营养不良症（FSHD），也称为兰杜齐 - 德热里纳病，是一种常染色体显性遗传性骨骼肌疾病，其命名依据是它所影响的不同肌肉群：面部、肩部和上臂。它是骨骼肌第三常见的遗传性退行性疾病，在所有受影响个体中没有特定模式。目前，这种疾病无法治愈，但有许多管理策略可用于改善生活质量并防止各个肌肉群进一步退化。本综述旨在深入探讨FSHD患者的管理策略，包括生活方式和医学干预。
相似文献
1
Management strategies in facioscapulohumeral muscular dystrophy.
Intractable Rare Dis Res. 2019 Feb;8(1):9-13. doi: 10.5582/irdr.2019.01016.
2
[Facioscapulohumeral muscular dystrophy. The spectrum of clinical manifestations and molecular genetic changes].
Nervenarzt. 2003 Feb;74(2):151-8. doi: 10.1007/s00115-002-1455-4.
3
Updating the Clinical Picture of Facioscapulohumeral Muscular Dystrophy: Ramifications for Drug Development With Potential Solutions.
Ther Innov Regul Sci. 2020 Jan;54(1):144-150. doi: 10.1007/s43441-019-00038-w. Epub 2020 Jan 6.
4
[Functional study of a gene candidate for Landouzy-Dejerine muscular dystrophy].
Bull Mem Acad R Med Belg. 2004;159(5-6):343-8; discussion 348-9.
5
Genetic Approaches for the Treatment of Facioscapulohumeral Muscular Dystrophy.
Front Pharmacol. 2021 Mar 12;12:642858. doi: 10.3389/fphar.2021.642858. eCollection 2021.
6
Muscle fibrosis as a prognostic biomarker in facioscapulohumeral muscular dystrophy: a retrospective cohort study.
Acta Neuropathol Commun. 2023 Oct 17;11(1):165. doi: 10.1186/s40478-023-01660-4.
7
Muscle MRI findings in facioscapulohumeral muscular dystrophy.
Eur Radiol. 2016 Mar;26(3):693-705. doi: 10.1007/s00330-015-3890-1. Epub 2015 Jun 27.
8
What's in a name? The clinical features of facioscapulohumeral muscular dystrophy.
Pract Neurol. 2016 Jun;16(3):201-7. doi: 10.1136/practneurol-2015-001353. Epub 2016 Feb 9.
9
Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD).
BMC Neurol. 2016 Aug 17;16:138. doi: 10.1186/s12883-016-0664-6.
10
The facioscapulohumeral muscular dystrophy - health index: Italian validation of a disease-specific measure of symptomatic burden.
Disabil Rehabil. 2024 May;46(10):2130-2137. doi: 10.1080/09638288.2023.2212181. Epub 2023 May 17.
引用本文的文献
1
Muscular Dystrophies.
Adv Exp Med Biol. 2025;1478:245-284. doi: 10.1007/978-3-031-88361-3_11.
2
Current landscape for the management of facioscapulohumeral muscular dystrophy and emerging treatment modalities: A literature review.
AIMS Neurosci. 2025 Jun 25;12(2):291-311. doi: 10.3934/Neuroscience.2025016. eCollection 2025.
3
Combined Lumbar-Sacral Plexus Block in Facioscapulohumeral Muscular Dystrophy for Hip Fracture Surgery: A Case Report.
Turk J Anaesthesiol Reanim. 2024 Feb 28;52(1):36-38. doi: 10.4274/TJAR.2024.231471.
4
Randomized phase 2 study of ACE-083, a muscle-promoting agent, in facioscapulohumeral muscular dystrophy.
Muscle Nerve. 2022 Jul;66(1):50-62. doi: 10.1002/mus.27558. Epub 2022 May 9.
5
DUX4 Transcript Knockdown with Antisense 2'-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy.
Mol Ther. 2021 Feb 3;29(2):848-858. doi: 10.1016/j.ymthe.2020.10.010. Epub 2020 Oct 15.
6
DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD.
FASEB J. 2020 Mar;34(3):4573-4590. doi: 10.1096/fj.201902696. Epub 2020 Feb 5.
本文引用的文献
1
Surgical correction of hyperlordosis in facioscapulohumeral muscular dystrophy: A case report.
BMC Surg. 2017 Jul 17;17(1):83. doi: 10.1186/s12893-017-0276-0.
2
The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature.
J Neuromuscul Dis. 2015;2(1):73-85.
3
Facioscapulohumeral Muscular Dystrophy.
Continuum (Minneap Minn). 2016 Dec;22(6, Muscle and Neuromuscular Junction Disorders):1916-1931. doi: 10.1212/CON.0000000000000399.
4
Spontaneous resolution of retinal vascular abnormalities and macular oedema in facioscapulohumeral muscular dystrophy.
Clin Exp Ophthalmol. 2016 Sep;44(7):627-628. doi: 10.1111/ceo.12735. Epub 2016 Apr 27.
5
Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular & Electrodiagnostic Medicine.
Neurology. 2015 Jul 28;85(4):357-64. doi: 10.1212/WNL.0000000000001783.
6
Trunk muscle involvement is most critical for the loss of balance control in patients with facioscapulohumeral muscular dystrophy.
Clin Biomech (Bristol). 2014 Sep;29(8):855-60. doi: 10.1016/j.clinbiomech.2014.07.008. Epub 2014 Aug 10.
7
Population-based incidence and prevalence of facioscapulohumeral dystrophy.
Neurology. 2014 Sep 16;83(12):1056-9. doi: 10.1212/WNL.0000000000000797. Epub 2014 Aug 13.
8
Facioscapulohumeral dystrophy: the path to consensus on pathophysiology.
Skelet Muscle. 2014 Jun 10;4:12. doi: 10.1186/2044-5040-4-12. eCollection 2014.
9
On the significance of retinal vascular disease and hearing loss in facioscapulohumeral muscular dystrophy.
Muscle Nerve Suppl. 1995(2):S73-80.
10
Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2.
Nat Genet. 2012 Dec;44(12):1370-4. doi: 10.1038/ng.2454. Epub 2012 Nov 11.
Zotero 插件